Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.10
NAS:AKCA's Cash-to-Debt is ranked lower than
99.99% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:AKCA: 1.10 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKCA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.1  Med: 5000.68 Max: No Debt
Current: 1.1
Equity-to-Asset -0.67
NAS:AKCA's Equity-to-Asset is ranked lower than
99.99% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AKCA: -0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AKCA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.67  Med: -0.62 Max: -0.56
Current: -0.67
-0.67
-0.56
Debt-to-Equity -1.30
NAS:AKCA's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:AKCA: -1.30 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:AKCA' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.3  Med: -1.26 Max: -1.22
Current: -1.3
-1.3
-1.22
Altman Z-Score: 0.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -357.65
NAS:AKCA's Operating Margin % is ranked lower than
99.99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:AKCA: -357.65 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AKCA' s Operating Margin % Range Over the Past 10 Years
Min: -357.65  Med: 0 Max: 0
Current: -357.65
-357.65
0
Net Margin % -362.12
NAS:AKCA's Net Margin % is ranked lower than
99.99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:AKCA: -362.12 )
Ranked among companies with meaningful Net Margin % only.
NAS:AKCA' s Net Margin % Range Over the Past 10 Years
Min: -362.12  Med: 0 Max: 0
Current: -362.12
-362.12
0
ROA % -160.42
NAS:AKCA's ROA % is ranked lower than
99.99% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:AKCA: -160.42 )
Ranked among companies with meaningful ROA % only.
NAS:AKCA' s ROA % Range Over the Past 10 Years
Min: -216.85  Med: -201.4 Max: -160.42
Current: -160.42
-216.85
-160.42
ROC (Joel Greenblatt) % -97692.13
NAS:AKCA's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:AKCA: -97692.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKCA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1228440  Med: -658721.07 Max: -89002.14
Current: -97692.13
-1228440
-89002.14
GuruFocus has detected 1 Warning Sign with Akcea Therapeutics Inc $NAS:AKCA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKCA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:AKCA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NYSE:EBS, NAS:XLRN, NAS:MYOK, NAS:INVA, NYSE:CBM, NYSE:BHVN, NAS:ARRY, NAS:LXRX, NAS:RGEN, NAS:DVAX, NAS:IMMU, NAS:GBT, NAS:SGMO, NAS:AIMT, NAS:ESPR, NAS:CORT, NAS:DERM, NAS:ACOR, NAS:INSM, NAS:FPRX » details
Traded in other countries:1KA.Germany,
Headquarter Location:USA
Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

Ratios

vs
industry
vs
history
PS Ratio 39.27
AKCA's PS Ratio is ranked lower than
99.99% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AKCA: 39.27 )
Ranked among companies with meaningful PS Ratio only.
AKCA' s PS Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 39.35
Current: 39.27
0
39.35
Price-to-Free-Cash-Flow 47.35
AKCA's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. AKCA: 47.35 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKCA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 47.45
Current: 47.35
0
47.45
Price-to-Operating-Cash-Flow 47.35
AKCA's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. AKCA: 47.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKCA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 47.45
Current: 47.35
0
47.45
EV-to-EBIT -20.24
AKCA's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AKCA: -20.24 )
Ranked among companies with meaningful EV-to-EBIT only.
AKCA' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.35  Med: 0 Max: 0
Current: -20.24
-21.35
0
EV-to-EBITDA -20.28
AKCA's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AKCA: -20.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKCA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.38  Med: 0 Max: 0
Current: -20.28
-21.38
0
Current Ratio 1.78
AKCA's Current Ratio is ranked lower than
99.99% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AKCA: 1.78 )
Ranked among companies with meaningful Current Ratio only.
AKCA' s Current Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.72 Max: 5.99
Current: 1.78
0.32
5.99
Quick Ratio 1.78
AKCA's Quick Ratio is ranked lower than
99.99% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AKCA: 1.78 )
Ranked among companies with meaningful Quick Ratio only.
AKCA' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.72 Max: 5.99
Current: 1.78
0.32
5.99

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -4.92
AKCA's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AKCA: -4.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKCA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.42  Med: 0 Max: 0
Current: -4.92
-11.42
0

More Statistics

EPS (TTM) $ -2.88
Short Percentage of Float3.32%
52-Week Range $8.10 - 25.73
Shares Outstanding (Mil)66.54
» More Articles for NAS:AKCA

Headlines

Articles On GuruFocus.com
Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada Sep 12 2017 
Akcea Therapeutics, Inc. (Nasdaq: AKCA) to Ring The Nasdaq Stock Market Closing Bell Sep 07 2017 
Akcea Expands Leadership Team in Preparation for First Commercial Launch Sep 05 2017 
Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA Aug 31 2017 
Akcea to Present at Wells Fargo Healthcare Conference Aug 29 2017 
Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the E Jul 27 2017 
Akcea Therapeutics Announces Closing of Initial Public Offering Jul 19 2017 
Akcea Therapeutics Announces Pricing of Initial Public Offering Jul 13 2017 

More From Other Websites
Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada Sep 12 2017
Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada Sep 12 2017
Akcea Therapeutics, Inc. (Nasdaq: AKCA) to Ring The Nasdaq Stock Market Closing Bell Sep 07 2017
Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data Sep 06 2017
Akcea Therapeutics Establishes Canadian Subsidiary Sep 06 2017
Akcea Expands Leadership Team in Preparation for First Commercial Launch Sep 05 2017
Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA Aug 31 2017
Akcea to Present at Wells Fargo Healthcare Conference Aug 29 2017
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up Aug 14 2017
Akcea Reports Financial Results and Highlights for Second Quarter 2017  Aug 08 2017
Sorry, Blue Apron. Appian is among the most successful IPOs of 2017 Aug 03 2017
Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the... Jul 27 2017
Akcea Therapeutics Announces Closing of Initial Public Offering Jul 19 2017
IPOs This Week: 5 Companies Seek Nearly $1 Billion in Capital Jul 16 2017
Akcea Therapeutics Announces Pricing of Initial Public Offering Jul 13 2017
Akcea Therapeutics prices IPO below expected range Jul 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}